Amarin Corp Plc (AMRN)

[sts66]

They already raised the price by 6% for 2019 - haven't announced it, but when you compare copays on Medicare.gov for 2018 vs. 2019 for the same plan it's clear as day. Raising prices by any larger amount in 2019 would be suicide - on T4 V is already expensive, making copays higher would lead to much less use because people just can't afford it. AMRN makes plenty of money with current pricing, no need to be greedy - just grow sales volumes and profits will roll in - well, after R-IT is approved and formularies change.